论文部分内容阅读
目的建立大鼠免疫损伤性肝纤维化的实验模型,研究中药复方肝纤愈对血清层黏蛋白(Laminin,LN)、透明质酸(Hyaluronic acid,HA)、血清Ⅲ型前胶原(Precollagen typeⅢ,PCⅢ)、肝脏羟脯氨酸(Hydroxyproline,Hyp)含量的影响,探讨其抗肝纤维化的作用机制。方法在以人血白蛋白诱导的免疫损伤性肝纤维化大鼠模型基础上,肝纤愈大、小剂量(12．2、6．1g/kg),灌胃给药,连续8周,以鳖甲软肝片和秋水仙碱为阳性对照药,放射性免疫方法测定大鼠血清中HA、LN、PCⅢ含量,化学法测定肝脏羟脯氨酸含量。同时观察肝脏组织病理学改变。结果肝纤愈大剂量组可明显降低人血白蛋白诱导免疫性肝纤维化大鼠模型血清中HA、LN、PCⅢ的含量,同时可降低大鼠肝脏中羟脯氨酸的含量。肝脏组织病理学有显著改善。结论肝纤愈通过对肝脏胶原物质代谢的影响而产生抗肝纤维化作用。
Objective To establish an experimental model of immune-impaired liver fibrosis in rats and to study the effects of traditional Chinese herbal compound liver fibrosis on serum laminin (LN), hyaluronic acid (HA), and serum type III procollagen (Precollagen type III, The effects of PCIII) and hydroxyproline (Hyp) content in liver were explored to explore the mechanism of anti-hepatic fibrosis. Methods On the basis of a rat model of immune-induced liver fibrosis induced by human serum albumin, the hepatic fibrosis was increased and the doses (12.2, 6.1 g/kg) were administered orally for 8 consecutive weeks. Biejia Ruangan Tablets and colchicine were positive control drugs. The contents of HA, LN and PCIII in rat serum were determined by radioimmunoassay. The content of hydroxyproline in liver was determined by chemical method. At the same time, the pathological changes of the liver were observed. Results The high-dose liver fibrosis group can significantly reduce the serum HA, LN, and PCIII levels in the rat model of immune hepatic fibrosis induced by human serum albumin, and at the same time reduce the content of hydroxyproline in rat liver. Liver histopathology has improved significantly. Conclusion Hepatic fibrosis has anti-hepatic fibrosis effect on the metabolism of liver collagen.